Ignite Creation Date:
2025-12-24 @ 2:29 PM
Ignite Modification Date:
2026-02-20 @ 1:40 PM
Study NCT ID:
NCT01626859
Status:
COMPLETED
Last Update Posted:
2021-04-12
First Post:
2012-06-19
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia
Sponsor:
Tanabe Pharma Corporation
Organization:
Study Overview
Official Title:
A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia (12 Weeks Treatment Study)
Status:
COMPLETED
Status Verified Date:
2021-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this study is to evaluate the pharmacokinetics, safety and efficacy of MP-214 in patients with schizophrenia.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: